Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Share

Report ID: GMI7991
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Acute Myeloid Leukemia Market Share

The acute myeloid leukemia industry is characterized by diverse players competing in the industry. Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, and Astellas Pharma Inc., account for significant market share. These prominent players adopt a combination of strategic initiatives to provide comprehensive range of products, such as collaboration & partnership, global expansion, research and development, diverse treatment modalities, market access and commercialization, product diversification, and regulatory compliance to maintain a competitive edge in the market.

Acute Myeloid Leukemia Market Companies

Foremost players operating in the acute myeloid leukemia industry are as mentioned below:

Astellas Pharma Inc.
Bristol Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals plc
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Partner Therapeutics, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for acute myeloid leukemia was valued at USD 2.1 billion in 2023 and is estimated to observe 10.7% CAGR between 2024 and 2032, attributed to advancement in technology, surging government initiatives, early diagnosis, coupled with efforts to implement screening programs.

The hospitals & clinics segment dominated the market in 2023 and is anticipated to record 9.8% CAGR from 2024 to 2032 as they are equipped with comprehensive facilities and specialized departments, including hematology-oncology units, where AML patients can receive integrated care.

In 2023, North America market for acute myeloid leukemia held a significant share of 38.4% and will grow rapidly through 2032 as the region boasts advanced healthcare infrastructure, including state-of-the-art hospitals, research facilities, and specialized cancer treatment centers.

Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Partner Therapeutics, Inc., Pfizer Inc., and Rigel Pharmaceuticals, Inc.